Please assess the completion status of the following clinical trial:

Trial Title: Multisite Observational Maternal and Infant Study for COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for Pregnancy Group (Group 1):~* Pregnant individuals who are scheduled to receive or have received complete vaccination series of any licensed or EUA SARS-CoV-2 vaccine during pregnancy. (NOTE: no limitation health status, or gestational age at enrollment)~* Willing and able to provide consent for study participation for herself and for her infant prior to initiation of any study procedures.~Inclusion Criteria for Postpartum Group (Group 3):~* Individuals who are scheduled to receive or who have initiated vaccination series of any licensed or EUA SARS-CoV-2 vaccine within the first 2 months postpartum. (NOTE: no limitation on health status).~* Willing and able to provide consent for study participation for herself and for her infant prior to initiation of any study procedures (a separate consent form will be used for their infants).~Inclusion Criteria for Additional Dose(s) During Pregnancy Group (Group 5):~* Pregnant individuals who received one dose or both doses of their primary vaccine series prior to pregnancy and are scheduled to receive or have received additional dose(s) of any licensed or EUA SARS-CoV-2 vaccine during pregnancy OR pregnant individuals who received complete vaccination series during pregnancy and are scheduled to receive or have received additional dose(s) of any licensed or EUA SARS-CoV-2 vaccine during pregnancy. (NOTE: no limitation on health status or gestational age at enrollment). This applies to individuals who have completed their primary series and receive an additional dose during pregnancy.~* Willing and able to provide consent for study participation for herself and for her infant prior to initiation of any study procedures.~Inclusion Criteria for All Participants:~* ≥18 years of age at time of enrollment~* Understands and agrees to comply with all study procedures.~* Agrees to sign medical release for herself and her infant to allow study staff to gather pertinent medical information, pregnancy outcome data, and medical information as needed.~Exclusion Criteria:~* Behavioral (including a history of alcohol or drug abuse within 1 year prior to study enrollment) or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.~* Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Individuals vaccinated during pregnancy (Type: None): Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
- Group 2: Individuals vaccinated postpartum (Type: None): Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
- Group 3: Infants of individuals vaccinated during pregnancy (Type: None): Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)
- Group 4: Infants of individuals vaccinated postpartum (Type: None): Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)
- Group 5: Individuals receiving additional vaccines during pregnancy (Type: None): Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 200 individuals).
- Group 6: Infants of individuals receiving additional vaccines during pregnancy (Type: None): Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 200 infants).

Based on this trial design, predict the completion outcome and termination type (if applicable).